Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis



Rating:

Share or cite this content

Citations should be made in the following way:
H. Taniguchi, Y. Kondoh, T. Kimura, K. Kataoka (Seto, Japan). Recombinant thrombomodulin improves survival in acute exacerbation of idiopathic pulmonary fibrosis. Eur Respir J 2012; 40: Suppl. 56, 2823

Member's Comments

No comment yet.

Related content which might interest you: A proof of concept study by thrombomodulin for acute exacerbations of idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Diffuse pulmonary fibrosis Year: 2013 Asymmetry in acute exacerbation of idiopathic pulmonary fibrosis Source: ERJ Open Res, 3 (2) 00036-2016; 10.1183/23120541.00036-2016 Year: 2017 Acute exacerbation of idiopathic pulmonary fibrosis Source: Eur Respir J 2004; 23: 792 Year: 2004 Tumor-associated antigens in acute exacerbation of idiopathic pulmonary fibrosis: Associations with disease activity Source: Annual Congress 2010 - Clinical aspects in pulmonary fibrosis Year: 2010 Acute exacerbations and pulmonary hypertension in advanced idiopathic pulmonary fibrosis Source: Eur Respir J 2012; 40: 93-100 Year: 2012 The challenge of acute exacerbation of pulmonary fibrosis Source: International Congress 2014 – PG01 Challenges faced when diagnosing idiopathic interstitial lung disease Year: 2014 Clinical predictors and explant lung pathology of acute exacerbation of idiopathic pulmonary fibrosis Source: ERJ Open Res, 6 (4) 00261-2019; 10.1183/23120541.00261-2019 Year: 2020 Modified GAP stage as a predictor of acute exacerbation in idiopathic pulmonary fibrosis Source: International Congress 2018 – Consequences of idiopathic interstitial pneumonias Year: 2018 Acute exacerbations of idiopathic pulmonary fibrosis and the role of corticosteroids Source: Breathe, 16 (3) 200086; 10.1183/20734735.0086-2020 Year: 2020 Pulmonary function measures predict mortality differently in IPF versus combined pulmonary fibrosis and emphysema Source: Eur Respir J 2011; 37: 176-183 Year: 2011 Differences of acute exacerbations in idiopathic pulmonary fibrosis compared to other fibrotic lung diseases Source: International Congress 2019 – The world of idiopathic pulmonary fibrosis Year: 2019 Predicting survival in newly diagnosed idiopathic pulmonary fibrosis: a 3-year prospective study Source: Eur Respir J 2012; 40: 101-109 Year: 2012 Effects of short-term pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis Source: Eur Respir J 2006; 28: Suppl. 50, 628s Year: 2006 Suppressed pulmonary expression of leptin in lipopolysaccharide-induced acute and chronic lung inflammation Source: Annual Congress 2006 - Novel pathogenic aspects of acute lung injury and acute respiratory distress syndrome (ARDS) Year: 2006 A novel chronic murine model of idiopathic pulmonary fibrosis Source: International Congress 2018 – Pulmonary fibrosis: from models to patients Year: 2018 High mobility group box protein 1 (HMGB1) production in highly vascularized alveolar lesions causes acute exacerbation in idiopathic pulmonary fibrosis Source: Annual Congress 2005 - Progresses in lung fibrosis Year: 2005 Prognostic factors analysis of patients with acute exacerbation of idiopathic interstitial pneumonias treated by polymyxin B hemoperfusion Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities Year: 2013 The efficacy of anti-fibrotic agents for acute exacerbation of idiopathic pulmonary fibrosis Source: International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside Year: 2017 High interleukin-33 is associated with acute exacerbation in patients with chronic obstructive pulmonary disease Source: Virtual Congress 2020 – Prediction of outcomes in obstructive diseases Year: 2020 Acute exacerbation of idiopathic pulmonary fibrosis as the initial presentation of the disease Source: Eur Respir Rev 2009; 18: 129-132 Year: 2009